Biocryst Pharmaceuticals (BCRX) Capital Leases (2015 - 2026)

Biocryst Pharmaceuticals' Capital Leases history runs 12 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• Quarterly Capital Leases fell 49.31% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 49.31% YoY) and the FY2025 annual result came in at $1.4 million, down 32.16% from the prior year.
• Capital Leases was $1.2 million for Q1 2026 at Biocryst Pharmaceuticals, down from $1.4 million in the prior quarter.
• Across five years, Capital Leases topped out at $2.8 million in Q4 2023 and bottomed at $1.2 million in Q1 2026.
• A 5-year average of $2.0 million and a median of $2.1 million in 2024 frame the typical range for Capital Leases.
• Annual changes were most pronounced in 2023 — Capital Leases jumped 60.1% — and 2026, when it sank 49.31%.
• Biocryst Pharmaceuticals' Capital Leases stood at $1.8 million in 2022, then soared by 60.1% to $2.8 million in 2023, then slipped by 25.34% to $2.1 million in 2024, then plunged by 32.16% to $1.4 million in 2025, then fell by 18.6% to $1.2 million in 2026.
• Business Quant data shows BCRX's Capital Leases at $1.2 million in Q1 2026, $1.4 million in Q4 2025, and $1.7 million in Q3 2025.